Latest stories on KYMR
Kymera Therapeutics, Inc. (KYMR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Seeking Alpha56 · neutralgeneral
Wolfe upgrades Kymera Therapeutics to Outperform on potential upside
The Fly61 · neutralanalyst
Kymera Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research
The Fly61 · neutralanalyst
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
StockTitan56 · neutralgeneral
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
GlobeNewswire56 · neutralgeneral
Guggenheim raises Kymera Therapeutics price target to $170 on STAT6 program
Investing.com Analyst Ratings61 · neutralanalyst
Kymera Therapeutics price target raised to $170 from $135 at Guggenheim
The Fly61 · neutralanalyst
Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript
The Motley Fool67 · bullishearnings
Kymera Therapeutics Price Target Raised To 135 From 119 At Morgan Stanley
The Fly61 · neutralanalyst
Kymera Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation
Seeking Alpha50 · neutralearnings
Oppenheimer raises Kymera Therapeutics price target on trial timing
Investing.com Analyst Ratings61 · neutralanalyst
Kymera targets year-end 2026 KT-621 AD data and maintains cash runway into 2029
Seeking Alpha58 · neutralproduct/pr
Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Kymera Therapeutics Q2 Earnings Call Highlights
Yahoo Finance67 · bullishearnings
Kymera Therapeutics GAAP EPS of -$0.62 beats by $0.12, revenue of $65M beats by $32.22M
Seeking Alpha68 · bullishearnings
Kymera Therapeutics, Inc. (KYMR) files 8-K
SEC 8-K50 · neutralgeneral
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
Business Insider59 · neutralgeneral
Kymera Therapeutics Q2 2026 Earnings Preview
Seeking Alpha55 · neutralearnings
Deutsche Bank initiates Kymera stock with Hold on valuation concerns
Investing.com Analyst Ratings50 · neutralanalyst
Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026
StockTitan50 · neutralgeneral
Guggenheim raises Kymera Therapeutics price target on IRF5 program
Investing.com Analyst Ratings61 · neutralanalyst
Kymera Therapeutics, Inc. (KYMR) files 8-K
SEC 8-K50 · neutralgeneral
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
StockTitan56 · neutralgeneral
Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm
PR Newswire42 · neutralgeneral